A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/55 (2006.01) A61K 31/137 (2006.01) A61K 31/439 (2006.01) A61K 31/485 (2006.01) A61K 45/06 (2006.01)
Patent
CA 2323805
The analgesic effectiveness of a narcotic agonist-antagonist analgesic is significantly potentiated by administering a narcotic agonist-antagonist analgesic together with at least one nontoxic NMDA receptor antagonist. The narcotic agonist-antagonist analgesic is selected from the group consisting of pentazocine, nalbuphine, butorphanol, buprenorphine, meptazinol, dezocine, nalorphine, cyclazocine and pharmaceutically acceptable salts thereof. The nontoxic NMDA receptor antagonist is at least one member selected from the group consisting of dextromethorphan, dextrophan, amantadine, memantine and pharmaceutically acceptable salts thereof.
Le pouvoir analgésique d'un analgésique narcotique agoniste-antagoniste est accru de façon notable si l'on administre ledit analgésique conjointement à au moins un antagoniste des récepteurs NMDA non toxique. L'analgésique est choisi dans le groupe comprenant la pentazocine, la nalbuphine, le butorphanol, la buprénorphine, le meptazinol, la dézocine, la nalorphine, la cyclazocine et leur sels pharmaceutiquement acceptables. L'antagoniste des récepteurs NMDA non toxique est au moins un élément choisi dans le groupe comprenant le dextrométhorphane, le dextrophane, l'amantadine, la mémantine et leurs sels pharmaceutiquement acceptables.
Algos Pharmaceutical Corporation
Mcfadden Fincham
LandOfFree
Analgesic combination comprising nmda receptor antagonists... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Analgesic combination comprising nmda receptor antagonists..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analgesic combination comprising nmda receptor antagonists... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1702699